Nicole Agostino, DO
Hematology & Oncology · West Reading, PANPI 1063565042
Payments from drug & device makers
What this record shows
This record is dominated by education: $330 of the $454 with a category attached, or 72.7%. Servier Pharmaceuticals LLC accounts for 70.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $330 and has fallen 82.1% since, to $59 in 2025. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 14 payments — averaging $32.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$319
- Caris MPI, Inc.$59
- Rigel Pharmaceuticals, Inc.$25
- Bristol Myers Squibb$24
- Merck$15
- Gilead$12
Across 13 payments — averaging $11,656 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$124K
- Genentech, Inc.$28K
What the payments were for
- Food & beverage$12427%
- Education$33073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 8 | $319 |
| Caris MPI, Inc. | 2 | $59 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| Merck | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$454 in reported general payments places this provider in the 30th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 45 | $567,683 |
| BrukinsaZanubrutinib | 40 | $544,611 |
| IbrancePalbociclib | 28 | $433,002 |
| XtandiEnzalutamide | 24 | $323,677 |
| RevlimidLenalidomide | 18 | $317,471 |
| KisqaliRibociclib Succinate | 23 | $306,518 |
| JakafiRuxolitinib Phosphate | 13 | $225,095 |
| ImbruvicaIbrutinib | 13 | $205,748 |
| PomalystPomalidomide | 12 | $191,647 |
| CalquenceAcalabrutinib Maleate | 13 | $176,690 |
| VenclextaVenetoclax | 16 | $93,327 |
| Abiraterone Acetate | 51 | $68,636 |
| EliquisApixaban | 44 | $28,751 |
| Imatinib Mesylate | 14 | $18,212 |
| XareltoRivaroxaban | 13 | $9,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $24 | $317,47118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in West Reading
- Andrew RettewWest Reading$164K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.